Načítá se...
A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome
BACKGROUND: Alcohol withdrawal syndrome (AWS) is a distressing condition, generally controlled by benzodiazepines (BZD's). Baclofen, a gamma-aminobutyric acid-B (GABA(B)) agonist, has also shown promising results in controlling AWS. As there are few studies comparing the efficacy and tolerabili...
Uloženo v:
| Vydáno v: | Biomed J |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Chang Gung University
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6138810/ https://ncbi.nlm.nih.gov/pubmed/27105601 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bj.2015.09.002 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|